Sarepta Therapeutics's gross profit for the
three
months ended in Dec. 2024 was $526 Mil. Sarepta Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $1,583 Mil.
Sarepta Therapeutics had a gross margin of 79.91% for the quarter that ended in Dec. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Sarepta Therapeutics was 98.14%. The lowest was 83.22%. And the median was 87.91%.
Sarepta Therapeutics Gross Profit Historical Data
The historical data trend for Sarepta Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sarepta Therapeutics's Gross Profit
For the Biotechnology subindustry, Sarepta Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,583 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sarepta Therapeutics had a gross margin of 79.91% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Sarepta Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Sarepta Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRPT has been successfully added to your 